Study on Cemsidomide and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Be 18 years or older and able to provide consent to participate.
• Have a confirmed diagnosis of multiple myeloma with measurable disease.
• Have received at least three previous treatments for multiple myeloma, including specific types of drugs and therapies, unless unavailable locally.
• Have good organ function as determined by medical tests.
• Any side effects from previous cancer treatments must have improved to a mild level or returned to baseline.
• Women must not be pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed during the study and for 30 days after the last treatment.
• Men must agree to use condoms during intercourse with women who can become pregnant and avoid donating sperm during the study and for 30 days after the last treatment.
• Participants must not donate blood during the study and for 30 days after the last treatment.

Exclusion Criteria

• Have multiple myeloma affecting the brain or spinal cord.
• Have certain other medical conditions, such as systemic light chain amyloidosis, POEMS syndrome, or myelodysplastic syndrome.
• Have been previously treated with cemsidomide.
• Have significant heart problems or diseases.
• Have had a blood clot within three months before joining the study.
• Have another cancer that has progressed or needed treatment in the past three years.
• Have an uncontrolled active infection.
• Have difficulty swallowing tablets.